MedTrace Logo

Evaluation of the Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults

NCT06938763 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-01-06

No results posted yet for this study

Summary

A Phase I, Randomized, Double-blinded, Placebo-Controlled First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of J4 Dry Powder Capsule after Oral Administration of Single and Multiple Ascending Doses to Healthy Adults

Conditions

  • Alzheimer Disease

Interventions

DRUG

J4

dry powder capsule

DRUG

Placebo

Placebo dry powder capsule

Sponsors & Collaborators

  • Academia Sinica, Taiwan

    lead OTHER

Principal Investigators

  • Yijuang Chern, Director of Institute of Biomedical Sciences, PhD · Academia Sinica, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-14
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06938763 on ClinicalTrials.gov